Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Leukemia
Leukemia
Molecular and Cytogenetic Assessments Infrequently Performed in Patients with CML Receiving First-Line Imatinib
Mark Knight
Play Video
Leukemia
MURANO: Venetoclax-Rituximab at Fixed Duration Beats Chemoimmunotherapy in Relapsed/Refractory CLL
Phoebe Starr
Phoebe Starr
Play Video
Leukemia
Nelarabine Therapy Up Front Boosts Survival in T-Cell Leukemia and Lymphoma
Phoebe Starr
Play Video
Leukemia
New Oral TKI Ponatinib Produces High Response Rates in Hard-to-Treat Leukemia
Wayne Kuznar
Play Video
Leukemia
New Targeted Agent Shows Significant Success in Treating Refractory Form of AML
Wayne Kuznar
Play Video
Leukemia
Next-Generation Sequencing Could Help Treatment Decisions in Acute Myeloid Leukemia
Chase Doyle
Play Video
Leukemia
Nilotinib Sustains Deeper Molecular Response versus Imatinib in Patients with Ph+ CML
Wayne Kuznar
Play Video
Leukemia
Nilotinib Yields Better Rates of Molecular Response Than Imatinib in Frontline Setting
Chase Doyle
Play Video
Leukemia
Novel Agents Will Completely Change CLL Treatment
Play Video
Leukemia
Novel Anti-CD20 Antibodies Show Promising Results in Unfit Patients with Chronic Lymphocytic Leukemia
Wayne Kuznar
Play Video
2
3
4
5
6
7
Page 5 of 7
Results 41 - 50 of 70